Active Biotech AB (publ)
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more
Active Biotech AB (publ) (BTPC) - Total Assets
Latest total assets as of September 2025: €17.00 Million EUR
Based on the latest financial reports, Active Biotech AB (publ) (BTPC) holds total assets worth €17.00 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Active Biotech AB (publ) - Total Assets Trend (2013–2024)
This chart illustrates how Active Biotech AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Active Biotech AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Active Biotech AB (publ)'s total assets of €17.00 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 63.4% |
| Accounts Receivable | €11.80 Million | 27.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €245.00K | 0.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Active Biotech AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Active Biotech AB (publ)'s current assets represent 90.7% of total assets in 2024, an increase from 50.4% in 2013.
- Cash Position: Cash and equivalents constituted 63.4% of total assets in 2024, up from 49.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 27.3% of total assets.
Active Biotech AB (publ) Competitors by Total Assets
Key competitors of Active Biotech AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Active Biotech AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Active Biotech AB (publ) generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Active Biotech AB (publ) is currently not profitable relative to its asset base.
Active Biotech AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 0.93 | 3.24 |
| Quick Ratio | 1.17 | 0.93 | 3.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.10 Million | € -800.00K | € 20.93 Million |
Active Biotech AB (publ) - Advanced Valuation Insights
This section examines the relationship between Active Biotech AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.13 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | €43.20 Million |
| Market Capitalization | $3.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Active Biotech AB (publ)'s assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Active Biotech AB (publ)'s assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Active Biotech AB (publ) (2013–2024)
The table below shows the annual total assets of Active Biotech AB (publ) from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €43.20 Million | -1.92% |
| 2023-12-31 | €44.05 Million | -13.64% |
| 2022-12-31 | €51.01 Million | -10.21% |
| 2021-12-31 | €56.80 Million | +76.66% |
| 2020-12-31 | €32.16 Million | -51.97% |
| 2019-12-31 | €66.95 Million | -77.86% |
| 2018-12-31 | €302.43 Million | -0.45% |
| 2017-12-31 | €303.81 Million | -26.42% |
| 2016-12-31 | €412.88 Million | -8.14% |
| 2015-12-31 | €449.44 Million | -37.80% |
| 2014-12-31 | €722.52 Million | -5.90% |
| 2013-12-31 | €767.81 Million | -- |